The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

X.h

Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

Publications

Dunogué B, Pagnoux C, Guillevin L

Churg-strauss syndrome: clinical symptoms, complementary investigations, prognosis and outcome, and treatment.

Seminars in respiratory and critical care medicine 2011 Jun;32;298-309 — 2011 Jun — 298-309

Wechsler ME, Pauwels R, Drazen JM

Leukotriene modifiers and Churg-Strauss syndrome: adverse effect or response to corticosteroid withdrawal?

Drug safety 1999 Oct;21;241-51 — 1999 Oct — 241-51

Green RL, Vayonis AG

Churg-Strauss syndrome after zafirlukast in two patients not receiving systemic steroid treatment.

Lancet (London, England) 1999 Feb 27;353;725-6 — 1999 Feb 27 — 725-6

Knoell DL, Lucas J, Allen JN

Churg-Strauss syndrome associated with zafirlukast.

Chest 1998 Jul;114;332-4 — 1998 Jul — 332-4

Holloway J, Ferriss J, Groff J, Craig TJ, Klinek M

Churg-Strauss syndrome associated with zafirlukast.

The Journal of the American Osteopathic Association 1998 May;98;275-8 — 1998 May — 275-8